好的文章其實好重要, 隨時可以打通我們的任督二脈, 練成這個 '士逹'神功. 可是什麼人會寫得一手好文章呢? 現在寫紙的人多如森林裡的樹木, 我自己都得半桶水, 寫給你看都浪費你的時間.

要在樹林裡找一棵樹, 其實都不容易

  1. An overview of clinical research: the lay of the land. Lancet, 359 (9300), 57.
  2. Descriptive studies: what they can and cannot do. Lancet, 359 (9301), 145. 
  3. Bias and causal associations in observational research. Lancet, 359 (9302), 248.
  4. Cohort studies: marching towards outcomes. Lancet, 359 (9303), 341.
  5. Case-control studies: research in reverse. Lancet, 359 (9304), 431.
  6. Generation of allocation sequences in randomised trials: chance, not choice. Lancet, 359 (9305), 515.
  7.  Allocation concealment in randomised trials: defending against deciphering. Lancet, 359 (9306), 614.
  8. Blinding in randomised trials: hiding who got what. Lancet, 359 (9307), 696.
  9.  Sample size slippages in randomised trials: exclusions and the lost and wayward. Lancet, 359 (9308), 781.
  10.  Uses and abuses of screening tests. Lancet, 359 (9309), 881.
  11. Unequal group sizes in randomised trials: guarding against guessing. Lancet, 359 (9310), 968.
  12. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet 2002;359:1686-89

　

Hosted by www.Geocities.ws

  1. Multiplicity in randomised trials I: endpoints and treatments The Lancet 2005; 365:1591-1595

  2. Multiplicity in randomised trials II: subgroup and interim analyses Lancet 2005; 365: 1657–61

  3. Sample size calculations in randomised trials: mandatory and mystical Lancet 2005; 365: 1348–53

  4. Subgroup analysis in randomised controlled trials:importance, indications, and interpretation Lancet 2005; 365: 176–86

  5. Can meta-analysis help target interventions at individuals most likely to benefit? Lancet 2005; 365: 341–46

    　

　

1